Extremely low gestational age newborns (ELGANs), born at less than 28 weeks' estimated gestational age, suffer the greatest consequences of prematurity. There have been significant advances in their care over the last several decades, but the prospects for major advances within traditional treatment modalities appear limited. An artificial placenta using extracorporeal life support (ECLS) has been investigated in the laboratory as a new advance in the treatment of ELGANs. We review the concept of an artificial placenta, the purported benefits, and the most recent research efforts in this area.
INTRODUCTION: A BRAVE NEW WORLD: THE ARTIFICIAL PLACENTA
For the last century, science fiction writers have imagined the possibility of an artificial placenta: a device which would allow humans to be 'manufactured' outside the womb, developing from a single cell to a viable, healthy infant. Aldous Huxley's Brave New World and the Wachowskis' The Matrix famously portrayed fluid-filled pods used for extrauterine gestation not only as a marvel of technical progress, but also as a method of authoritarian control over the individual. An artificial placenta may appear far beyond the reach of modern science, but the idea of creating a life support system to maintain growing fetuses in a womb-like environment with extracorporeal support was first investigated 60 years ago. The motivation for developing a real-life artificial placenta is to radically improve the treatment of extreme prematurity by recreating the intrauterine environment.
COMPLICATIONS OF PREMATURITY: PREDICTABLE AND INTRANSIGENT
Preterm birth [birth before 37 weeks' estimated gestational age (EGA)] occurs in approximately 11% of births in the United States. It is the leading cause of neonatal morbidity and mortality in industrialized nations, accounting for 60-80% of deaths in infants without congenital anomalies [1] . Premature birth and the sudden transition to postnatal life are disruptive to premature infants, who are in a period of rapid growth and maturation. Although all premature infants are at risk for complications, extremely low gestational age newborns (ELGANs), defined as EGA less than 28 weeks, suffer the greatest mortality and morbidity.
Prematurity leads to complications that involve a wide range of physiologic systems and have both short-term and long-term effects. Short-term complications include persistent patent ductus arteriosus, intraventricular hemorrhage, periventricular leukomalacia, sepsis, retinopathy of prematurity, necrotizing enterocolitis, and respiratory distress syndrome (RDS). Long-term morbidities include neurodevelopmental sequelae (cerebral palsy, cognitive delay, blindness, and deafness), chronic lung disease, failure to thrive, and feeding difficulties [2] . Acute respiratory failure is by far the most significant cause of morbidity and mortality in prematurity. This can be because of the failure of the lungs to fully develop, persistent pulmonary hypertension of the newborn, parenchymal lung disease, or a combination of these. Bronchopulmonary dysplasia (BPD) remains the most common long-term complication, affecting at least 40% of ELGANs with severity proportional to the degree of prematurity [3, 4] .
ADVANCES IN THE TREATMENT OF PREMATURITY: REVOLUTIONARY TREATMENTS NOW PLATEAUED
Over the last century, many advances have been made in the treatment of preterm infants which have significantly improved patient outcomes. Prior to the 1940s, neonatal care for premature babies was barely existent as few infants below 1500 g survived [5] . Dr Hess [6] published some of the earliest outcomes data on premature infants in 1953, demonstrating that more than half of the surviving infants survived without handicap with only 15% of survivors showing severe handicap. Although these outcomes were skewed because of selection bias, this and other reports led to the establishment of premature nurseries in the 1950s and 1960s.
Revolutionary advances in the treatment of prematurity were made in the subsequent decades with administration of steroids to mothers before premature delivery, advanced mechanical ventilation, and exogenous surfactant. In the 1970s, there was growing evidence that giving mothers glucocorticoids prior to preterm delivery resulted in a decreased incidence of RDS by promoting lung maturation [7, 8] . The benefits of maternal steroids in accelerating lung maturity have been confirmed in recent studies [9] and this is now the standard of care. Also during the 1970s, new ventilator strategies including intermittent mandatory ventilation (IMV) and continuous positive airway pressure (CPAP) were adopted for the care of RDS in neonates [10] . These led to improved survival and a decreased incidence of BPD. Further technological advances followed, including high-frequency oscillator ventilation (HFOV) in 1980 after being demonstrated in a canine model by Bohn et al. [11] and being proven well tolerated in humans the same year [12] . HFOV, along with high-frequency jet ventilation, has been used increasingly in the care of neonates with RDS after evidence that it is at least equivalent to conventional ventilation [13] . In the 1980s, intratracheal exogenous surfactant was introduced. Strong evidence demonstrated the efficacy of surfactant in the prevention and treatment of RDS with improved survival in very premature infants [14] [15] [16] .
Over the last few decades, the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN) have reported trends in the morbidity and mortality among very low birth weight (VLBW) infants, demonstrating that increased improvements in prenatal, obstetric, and neonatal care have translated to increased survival [2, 3] . However, recent evidence suggests that a plateau has occurred and there has been no significant increase in the survival rates of VLBW infants without long-term morbidity [17] . Furthermore, the transition of pulmonary parenchyma from the canalicular to the saccular stage of development occurs between 22 and 24 weeks' gestation, marking the earliest time the lungs can effectively exchange gas, and therefore a significant barrier for the effectiveness of mechanical ventilation.
KEY POINTS
The artificial placenta is the ideal life-support system for premature infants as it has the potential to recreate the intrauterine environment and maintain fetal circulation.
ELGANs suffer the most severe consequences of prematurity and represent the population most likely to benefit from the artificial placenta.
VV-ECLS represents an advance in the artificial placenta, with the potential to overcome a number of historical limitations to artificial placenta support.
Although great strides have been made in ECLS and artificial placenta technology, challenges remain in the development of an artificial placenta prior to clinical translation.
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PARADIGM SHIFT: EXTRACORPOREAL SUPPORT
Over the last 60 years, many novel strategies have been proposed to improve the survival of premature infants physiologically and developmentally unprepared to thrive outside the womb. After Gibbon developed the 'heart-lung machine' in the 1950s, researchers began work on extracorporeal support for premature infants and called their system the 'artificial placenta'. Although premature infants appeared ideally suited for extracorporeal support, this technology was new, and the physiology and complications of extreme prematurity were poorly understood. It was a brilliant idea that could not be realized at the time: the possibility of using extracorporeal life support (ECLS) to recreate the intrauterine environment and preserve fetal circulation to allow more time for fetal development became an overarching goal for research.
HISTORY OF EXTRACORPOREAL MEMBRANE OXYGENATION: EXTRACORPOREAL SUPPORT FOR NEAR-TERM AND TERM INFANTS FLOURISHES
Given the morbidity and mortality associated with neonatal respiratory failure, alternative approaches to the current treatment modalities were considered in the 1970s. Prolonged extracorporeal circulation and gas exchange was first demonstrated in 1975 [18] . As a result of the concerns regarding the risks of bleeding in premature infants, its use was focused on full-term and near-term neonates with respiratory failure [19] . Given the risks of bleeding and circuit requirements, empiric extracorporeal membrane oxygenation (ECMO) inclusion criteria remain EGA at least 34 weeks and weight at least 2 kg. A series of neonatal ECMO patient outcomes was published in 1982 and reported 45 cases with a survival rate of 50% [20] . Subsequently, two randomized controlled trials of ECMO for neonates with neonatal respiratory failure were published, showing high survival rates of 100% [21] and 98% [22] . As ECMO continued to improve, inclusion criteria expanded.
The terminology describing ECLS in infants has been partitioned depending on the patient's gestational age at initiation of ECMO (Table 1) . For infants of at least 34 weeks' EGA, ECLS is generally called ECMO, is similar to ECMO used in adults or children, and is the standard of care for refractory respiratory and cardiac failure. Between 29 and 33 weeks' EGA, ECLS is referred to as 'preemie ECMO'; it has been proven clinically feasible, albeit with reduced survival rates and increased rates of intraventricular hemorrhage. 'Preemie ECMO' has been selectively used for severe respiratory failure in premature infants down to 29 weeks' gestational age, with birth weights as low as 1.1 kg [23] . Before 28 weeks' EGA, ECLS is termed an 'artificial placenta' and currently remains in the realm of laboratory research.
EXTRACORPOREAL LIFE SUPPORT DEFINITIONS
ECMO in children and adults is used in one of two modes, either venoarterial or venovenous. Venoarterial (VA)-ECMO has traditionally been used for patients with cardiac or cardiopulmonary failure, whereas venovenous (VV)-ECMO is used in cases of isolated respiratory failure [24] . The first generation of ECMO devices was used from 1975 to 2008. The new generation of ECMO devices, marked by the advent of centrifugal pumps, polymethylpentene oxygenators, and specialized cannulas, is termed 'ECMO II' [25] . In an artificial placenta, the umbilical vessels are used, which changes the ECMO configurations and nomenclature. The umbilical vein is always used for inflow. Blood can be pumped from the patient by his or her own heart via the umbilical artery [arteriovenous (AV)-ECLS], or augmented with a pump. Alternatively, an external pump can support drainage of blood from the jugular vein [venovenous (VV)-ECLS].
An artificial placenta is generally defined by four characteristics: maintenance of fetal circulation and recreation of the intrauterine environment including a low partial pressure of oxygen, lack of mechanical ventilation, simulated fetal breathing with fluid-filled lungs, and incorporation of either AV-ECLS or VV-ECLS [26] . The major obstacle to the current use of extracorporeal support in premature babies, the elevated risk of intracranial hemorrhage with heparinization, will need to be addressed with a fifth element of the artificial placenta, nonthrombogenic surfaces requiring little to no heparin. 
PATIENT SELECTION FOR THE ARTIFICIAL PLACENTA
The patients most likely to benefit from artificial placenta support are ELGANs (<28 weeks' EGA). Identification of those infants at highest risk for mortality will be critical for application of the artificial placenta in phase I clinical trials, likely using a pairmatched study design. Infants at high risk for mortality can be identified within the first hour of life or the first 12 h of life using the Clinical Risk Index for Babies (CRIB II) or the Score for Neonatal Acute Physiology-Perinatal Extension II (SNAPPE II), respectively [27, 28] . The overall mortality and morbidity of ELGANs have remained substantial; infants at 22-25 weeks' EGA are reported to have 49% mortality by 18-22 months, 61% mortality or profound impairment, and 73% mortality or impairment [29] .
THE ARTIFICIAL PLACENTA: EARLY HISTORY
In the 1950s, extracorporeal circulation was proposed as a way to treat prematurity-related lung failure. In 1958, Westin et al. [30] described a watertight arteriovenous perfusion system on human fetuses. These experiments were followed in 1965 by Callaghan et al. [31] , who attempted to connect a gas exchanger to the umbilical vessels in an arteriovenous circuit in nine lambs. This method met with little success. In 1969, Zapol et al. [32] had more success keeping an exteriorized fetal sheep alive for 55 h. Interest in this work decreased when the aforementioned advances in steroid administration, ventilation, and surfactant use were made in perinatal care. The artificial placenta was not truly revisited until 1979, when Griffith et al. [33] demonstrated the feasibility of the artificial placenta in mechanically ventilated animals and showed an inverse relationship between arterial oxygenation and pulmonary vascular resistance. During the 1980s, a group headed by Dr Kuwabara began an impressive body of research on the artificial placenta. They initially described their experience with ex-utero support of 50 fetal goats using AV-ECLS circuit with a pump. During this study, they refined their model, including using an arterial reservoir, to improve survival time up to 165 h [34] . Further modifications of the incubation system lead to improved survival in subsequent studies with a mean of 146 h and as long as 236 h [35] . Unno et al. [36] made further modifications using AV-ECLS with the implementation of a sedative (diazepam) and muscle relaxant (pancuronium) achieving survival in two sheep of 494 and 534 h, followed by successful transition to a ventilator for 1 week. This group went on to demonstrate that ongoing fetal lung growth and maturation was possible with artificial placenta support [37] . In subsequent studies, this group shifted their focus and investigated fetal metabolic and endocrine responses to changes in ambient temperature [38] , using a closed-circuit ring centrifugal pump with pulsatile flow with survival up to 234 h [39] , and the behavior cycles that normally exist late in fetal life [40] . These studies served as the initial building blocks toward the goal of an artificial placenta and are the foundation for recent artificial placenta research.
THE ARTIFICIAL PLACENTA: RECENT ADVANCES
Two of the technical difficulties with earlier artificial placenta circuits were high priming volumes and high-resistance oxygenators. This led to research into the use of a pumpless AV-ECLS system to avoid these issues, which has met with limited success [41] [42] [43] . Although short-term fetal circulation and adequate gas exchange were maintained, our experience with pumpless AV-ECLS revealed umbilical artery vasospasm, high circuit resistance, and cardiac failure [42] . Two groups recently pursued this type of circuit. Arens et al. [43] described the development of the NeonatOx oxygenator with a more than four-fold reduction in size of the oxygenator with good gas exchange properties, and Miura et al. [44 && ] described their experience with a pumpless AV-ECLS circuit which supported a lamb for 18.2 AE 3.2 h survival. Both utilized the umbilical vessels, no pump, and a prototype oxygenator with a small priming volume. Despite adding a pump to the AV-ECLS system, we encountered refractory hypotension (G.B. Mychaliska, unpublished observation). Although the simplicity is appealing, the clinical utility of a pumpless AV-ECLS circuit in humans seems technically infeasible because of the small size of the human umbilical artery, its tortuous anatomy, and the need for prolonged support with hemodynamic stability.
We hypothesized that an altered mode of extracorporeal support with inflow via the umbilical vein and outflow via the right jugular vein would solve the problem of hypotension by eliminating the variable of vasoreactivity of the umbilical arteries, and still maintain fetal circulation and stable gas exchange. Furthermore, VV-ECLS has the following translational advantages: passive drainage from the right atrium via the right internal jugular using a 6-8F cannula which decreases negative pressure and blood trauma; eliminating the need for an external reservoir; and the VV-ECLS circuit works in parallel to the fetal circulation, creating little increase in resistance and afterload. In AV-ECLS, because the circuit and oxygenator are placed in series, there is increased resistance, which can contribute to cardiac failure [45] .
We have created a sheep model of VV-ECLS and have demonstrated long-term support (>24 h, n ¼ 5) with stable gas exchange and hemodynamics ( Fig. 1 ) [46 && ]. During these experiments, sheep were delivered prematurely by cesarean section and cannulated while on native placental support. Initially, they were maintained in an artificial amniotic bath, but it was noted to become easily infected, causing sepsis in sheep which lived more than 24 h. This led us to maintain the sheep in an incubator, with an endotracheal tube filled with amniotic fluid and capped.
Next, we hypothesized that the artificial placenta could be applied after a trial of mechanical ventilation, and fetal circulation would be reinitiated. In premature lambs, mechanical ventilation failed within 1 h, and subsequently six of seven lambs were then successfully transitioned to the artificial placenta and survived for 24 h [47 && ]. Subsequent work has focused on the sheep models of extreme prematurity (equivalent to a 24-week human), lung development, brain function, development of nonthrombogenic surfaces, and survival after weaning from the artificial placenta. Although much progress has been made, many challenges remain for model development and clinical translation (Table 2) .
CONCLUSION
Aldous Huxley's 'decanting bottles' used to gestate the fetuses of a dystopian London remain a science fiction, but the development of a real artificial placenta is feasible and holds the promise of changing the paradigm in the treatment of extreme prematurity. Sixty years ago, enlightened researchers recognized that ELGANs are the ideal patients for extracorporeal support. Today, we have many elements of the necessary technology, and conceptual understanding of the physiology of extreme prematurity, to recreate the intrauterine environment. In the near future, we expect to be able to use an artificial placenta to allow premature babies to further develop, preparing them to thrive in a new world.
